DMARD blood monitoring and adverse effects — Rapid

Synopsis

Operate safe shared monitoring for conventional, biologic and targeted DMARDs, act on trajectories as well as thresholds, and connect symptoms and organ toxicity to withholding, urgent care, investigation and safe restart.

Baseline monitoring answers whether a medicine can start; serial monitoring asks whether dose and risk remain safe; symptom monitoring catches toxicity that blood tests cannot predict.
Name one responsible team for every result, specify the next due date and define who can withhold and restart treatment before shared care begins.
Methotrexate, leflunomide and sulfasalazine commonly need FBC, liver and renal testing every two weeks during early titration, monthly for the next three months and at least every twelve weeks when stable, adjusted to current BSR and local risk protocols.

Key red flags

Fever, rigors, hypotension or focal severe infection with neutropenia is a medical emergency requiring immediate broad-spectrum antimicrobial care.

Marrow toxicity symptoms

Fever, oral ulcers, sore throat, bruising, bleeding, pallor or severe fatigue requires an immediate count and drug hold rather than waiting for routine monitoring.

Investigation priorities

First-line FBC with differential and plateletsFirst stepFirst line

Detect cytopenia and establish the direction and speed of change.

Management branches

Baseline and transferMake monitoring ownership explicit

A DMARD is started or care is transferred to a shared-care prescriber.

Complete medicine-specific baseline tests, infection and pregnancy assessment and document the starting dose, expected titration and adverse-effect safety net.
Set each test date and action threshold and identify which clinician reviews results and which may authorise prescription, withholding and restart.

Early and stable scheduleReduce frequency only when risk is truly stable

Conventional DMARD dose and results are moving from initiation to maintenance.

Key medicines

Methotrexate monitoringCheck FBC, liver profile and renal function commonly every two weeks until the dose is stable for six weeks, monthly for three months, then at least every twelve weeks while stable, using the current risk-adjusted shared-care protocol.

Leflunomide monitoringCheck FBC, liver profile and renal function every two weeks until stable for six weeks, monthly for three months and at least every twelve weeks when stable; monitor blood pressure regularly.

Open full textbook →Answer 2 questions